Non-Surgical Management of Recurrent Naso-Orbital Hemangiomas with Bevacizumab: A Case Report

Abstract

Shengyang Liu,1 Hui Zhao,2 Li Shi,1 Hongzhi Ji1 1Department of Otorhinolaryngology Head and Neck Surgery, Shandong Provincial ENT Hospital, Shandong University, Jinan, People’s Republic of China; 2Department of Radiology, Shandong Second Provincial General Hospital, Jinan, People’s Republic of ChinaCorrespondence: Hongzhi Ji, Department of Otorhinolaryngology Head and Neck Surgery, Shandong Provincial ENT Hospital, Shandong University, 4 Duanxing West Road, Jinan, 250000, People’s Republic of China, Email [email protected]: In this case report, we describe a 21-year-old man with recurrent hemangiomas in his left eye socket and nasal cavity. Traditional surgeries were unsuccessful, so we used Bevacizumab, a drug that inhibits blood vessel growth. This approach significantly reduced the tumor size and stopped frequent nosebleeds. Over two years, the tumor remained controlled without major side effects, suggesting Bevacizumab as a promising non-surgical treatment for recurrent hemangiomas.Keywords: Bevacizumab, orbital hemangioma, vascular endothelial growth factor, treatment efficacy

Keywords

• bevacizumab
• orbital hemangioma
• vascular endothelial growth factor
• treatment efficacy